Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Gross Margin (2016 - 2025)

Historic Gross Margin for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to 56.02%.

  • Anika Therapeutics' Gross Margin fell 96400.0% to 56.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 54.74%, marking a year-over-year decrease of 200700.0%. This contributed to the annual value of 63.38% for FY2024, which is 49400.0% down from last year.
  • Anika Therapeutics' Gross Margin amounted to 56.02% in Q3 2025, which was down 96400.0% from 50.9% recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Gross Margin registered a high of 66.69% during Q2 2024, and its lowest value of 199.14% during Q4 2023.
  • Over the past 5 years, Anika Therapeutics' median Gross Margin value was 58.23% (recorded in 2021), while the average stood at 35.33%.
  • In the last 5 years, Anika Therapeutics' Gross Margin plummeted by -1860700bps in 2022 and then soared by 2551000bps in 2024.
  • Quarter analysis of 5 years shows Anika Therapeutics' Gross Margin stood at 50.62% in 2021, then crashed by -368bps to 135.45% in 2022, then crashed by -47bps to 199.14% in 2023, then soared by 128bps to 55.96% in 2024, then grew by 0bps to 56.02% in 2025.
  • Its Gross Margin was 56.02% in Q3 2025, compared to 50.9% in Q2 2025 and 56.1% in Q1 2025.